within Pharmacolibrary.Drugs.ATC.N;

model N05AL06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Veralipride is a benzamide neuroleptic and dopamine D2 receptor antagonist that was used mainly for the treatment of vasomotor symptoms associated with menopause such as hot flashes. It is not approved or marketed in most countries today due to concerns over adverse effects and long-term safety.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters in healthy adult women, based on limited published data and general class properties (benzamide antipsychotics). No primary PK study with exact parameters available in PubMed or regulatory documentation.</p><h4>References</h4><ol><li><p>Plusquellec, Y, et al., &amp; Houin, G (1987). A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. <i>Journal of pharmacokinetics and biopharmaceutics</i> 15(3) 225–239. DOI:<a href=&quot;https://doi.org/10.1007/BF01066319&quot;>10.1007/BF01066319</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3668801/&quot;>https://pubmed.ncbi.nlm.nih.gov/3668801</a></p></li><li><p>Staveris, S, et al., &amp; Houin, G (1988). Pharmacokinetics of veralipride after chronic administration in humans. <i>Journal of pharmaceutical sciences</i> 77(1) 64–67. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600770111&quot;>10.1002/jps.2600770111</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3346823/&quot;>https://pubmed.ncbi.nlm.nih.gov/3346823</a></p></li><li><p>Godfrey, KR, et al., &amp; Bryant, R (2011). Modelling the Double Peak Phenomenon in pharmacokinetics. <i>Computer methods and programs in biomedicine</i> 104(2) 62–69. DOI:<a href=&quot;https://doi.org/10.1016/j.cmpb.2010.03.007&quot;>10.1016/j.cmpb.2010.03.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20381191/&quot;>https://pubmed.ncbi.nlm.nih.gov/20381191</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AL06;
